Effect of Androgel [testosterone] on atherogenesis, inflammation, cardiovascular risk factors and adiposity in type 2 diabetic males with hypogonadotrophic hypogonadism: A prospective, randomized and controlled-study
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2016
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- 15 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 23 Jun 2010 'Abbott Laboratories' added as trial sponsor as reported by ClinicalTrials.gov.